This segment focuses on the research, development, and clinical trials of therapeutics targeting complement-mediated diseases. The primary focus is on Narsoplimab (OMS721/MASP-2), a MASP-2 inhibitor, which has completed pivotal studies for HSCT-TMA and is in Phase III trials for IgAN and aHUS. Research and development activities include ongoing clinical trials, data analysis, and regulatory submissions. The company utilizes advanced technologies to develop and manufacture these therapies. The patient impact is significant, as these diseases often have limited treatment options. Market positioning is based on first-in-class potential and addressing unmet medical needs. Future opportunities include expanding the indications for Narsoplimab and developing other complement pathway inhibitors. Regulatory and clinical aspects involve navigating FDA and EMA approval processes. Partnerships include collaborations with research institutions and patient advocacy groups.

This segment is dedicated to developing treatments for addiction and compulsive disorders. The primary focus is on PPAR? (OMS405) in Phase II trials for opioid and nicotine addiction, and PDE7 (OMS527) in Phase I trials for addiction, compulsive disorders, and movement disorders. Research and development activities include clinical trials, preclinical studies, and formulation development. The company utilizes small-molecule drug discovery and development technologies. The patient impact is aimed at addressing the significant unmet needs in addiction treatment. Market positioning is based on targeting novel pathways and addressing a growing public health crisis. Future opportunities include expanding the pipeline and exploring combination therapies. Regulatory and clinical aspects involve navigating FDA approval processes for these novel treatments. Partnerships may include collaborations with addiction treatment centers and research institutions.

This segment focuses on developing therapies for various cancers, including those related to dysfunction of the immune system. Research and development activities include preclinical programs such as GPR174 Inhibitors and Chimeric Antigen Receptor (CAR) T-Cell and Adoptive T-Cell Therapies. The company utilizes advanced technologies in immuno-oncology, including CAR-T cell therapy and small-molecule inhibitors. The patient impact is aimed at improving outcomes for cancer patients. Market positioning is based on targeting novel pathways and developing innovative immunotherapies. Future opportunities include expanding the pipeline and exploring combination therapies. Regulatory and clinical aspects involve navigating FDA approval processes for these novel treatments. Partnerships may include collaborations with cancer research centers and pharmaceutical companies.